The likelihood of persistent arthritis increases with the level of anti-citrullinated peptide antibody and immunoglobulin M rheumatoid factor: A longitudinal study of 376 patients with very early undifferentiated arthritis

Arthritis Research and Therapy

Volumn 12, Issue 3, 2010, Pages

  Mjaavatten, Maria D ^a   Heijde, Désirée V D ^a,b   Uhlig, Till ^a   Haugen, Anne J ^c   Nygaard, Halvor ^d   Sidenvall, Göran ^e   Helgetveit, Knut ^f   Kvien, Tore K ^a  

^a DIAKONHJEMMET HOSPITAL   (Norway)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Ostfold Hospital Trust   (Norway)

^d Hospital for Rheumatic Diseases   (Norway)

^e Innlandet Hospital   (Norway)

^f Martina Hansens Hospital   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; IMMUNOGLOBULIN M; RHEUMATOID FACTOR; ANTIIDIOTYPIC ANTIBODY; CYCLIC CITRULLINATED PEPTIDE; CYCLOPEPTIDE;

ADULT; ARTHRITIS; ARTICLE; DISEASE COURSE; DISEASE DURATION; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PERSISTENT ARTHRITIS; PREDICTIVE VALUE; SENSITIVITY AND SPECIFICITY; STATISTICAL MODEL; UNDIFFERENTIATED ARTHRITIS; VISUAL ANALOG SCALE; AGED; BLOOD; CLINICAL TRIAL; COHORT ANALYSIS; IMMUNOLOGY; MIDDLE AGED; NORWAY; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; TIME;

ADULT; AGED; ANTIBODIES, ANTI-IDIOTYPIC; ARTHRITIS; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOGLOBULIN M; LOGISTIC MODELS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NORWAY; PEPTIDES, CYCLIC; PREDICTIVE VALUE OF TESTS; RHEUMATOID FACTOR; RISK ASSESSMENT; ROC CURVE; SENSITIVITY AND SPECIFICITY; TIME FACTORS; YOUNG ADULT;

EID: 77951784468     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar2995     Document Type: Article

References (33)

1. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-324. 10.1002/art.1780310302, 3358796.
2. Scott DL. Prognostic factors in early rheumatoid arthritis. Rheumatology (Oxford) 2000, 39:24-29.
3. Avouac J, Gossec L, Dougados M. Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review. Ann Rheum Dis 2006, 65:845-851. 10.1136/ard.2006.051391, 1798205, 16606649.
4. Helm-van Mil AH, le Cessie S, van Dongen H, Breedveld FC, Toes RE, Huizinga TW. A prediction rule for disease outcome in patients with recent-onset undifferentiated arthritis: how to guide individual treatment decisions. Arthritis Rheum 2007, 56:433-440. 10.1002/art.22380, 17265478.
5. Jansen AL, Horst-Bruinsma IE, van Schaardenburg D, Stadt RJ, de Koning MH, Dijkmans BA. Rheumatoid factor and antibodies to cyclic citrullinated peptide differentiate rheumatoid arthritis from undifferentiated polyarthritis in patients with early arthritis. J Rheumatol 2002, 29:2074-2076.
6. Schellekens GA, Visser H, de Jong BA, Hoogen FH, Hazes JM, Breedveld FC, van Venrooij WJ. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 2000, 43:155-163. 10.1002/1529-0131(200001)43:1<155::AID-ANR20>3.0.CO;2-3, 10643712.
7. van Gaalen FA, Linn-Rasker SP, van Venrooij WJ, de Jong BA, Breedveld FC, Verweij CL, Toes RE, Huizinga TW. Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study. Arthritis Rheum 2004, 50:709-715. 10.1002/art.20044, 15022309.
8. Nishimura K, Sugiyama D, Kogata Y, Tsuji G, Nakazawa T, Kawano S, Saigo K, Morinobu A, Koshiba M, Kuntz KM, Kamae I, Kumagai S. Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med 2007, 146:797-808.
9. Syversen SW, Gaarder PI, Goll GL, Ødegård S, Haavardsholm EA, Mowinckel P, Heijde DM, Landewe R, Kvien TK. High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis: results from a 10-year longitudinal study. Ann Rheum Dis 2008, 67:212-217. 10.1136/ard.2006.068247, 17526555.
10. Banal F, Dougados M, Combescure C, Gossec L. Sensitivity and specificity of the American College of Rheumatology 1987 criteria for the diagnosis of rheumatoid arthritis according to disease duration: a systematic literature review and meta-analysis. Ann Rheum Dis 2009, 68:1184-1191. 10.1136/ard.2008.093187, 18728049.
11. van Dongen H, van Aken J, Lard LR, Visser K, Ronday HK, Hulsmans HM, Speyer I, Westedt ML, Peeters AJ, Allaart CF, Toes RE, Breedveld FC, Huizinga TW. Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2007, 56:1424-1432. 10.1002/art.22525, 17469099.
12. Wiles N, Symmons DP, Harrison B, Barrett E, Barrett JH, Scott DG, Silman AJ. Estimating the incidence of rheumatoid arthritis: trying to hit a moving target?. Arthritis Rheum 1999, 42:1339-1346. 10.1002/1529-0131(199907)42:7<1339::AID-ANR6>3.0.CO;2-Y, 10403260.
13. Visser H, le Cessie S, Vos K, Breedveld FC, Hazes JM. How to diagnose rheumatoid arthritis early: a prediction model for persistent (erosive) arthritis. Arthritis Rheum 2002, 46:357-365. 10.1002/art.10117, 11840437.
14. El Miedany Y, Youssef S, Mehanna AN, El Gaafary M. Development of a scoring system for assessment of outcome of early undifferentiated inflammatory synovitis. Joint Bone Spine 2008, 75:155-162. 10.1016/j.jbspin.2007.04.021, 17980637.
15. Green M, Marzo-Ortega H, McGonagle D, Wakefield R, Proudman S, Conaghan P, Gooi J, Emery P. Persistence of mild, early inflammatory arthritis: the importance of disease duration, rheumatoid factor, and the shared epitope. Arthritis Rheum 1999, 42:2184-2188. 10.1002/1529-0131(199910)42:10<2184::AID-ANR20>3.0.CO;2-2, 10524691.
16. Harrison B, Symmons D. Early inflammatory polyarthritis: results from the Norfolk Arthritis Register with a review of the literature. II. Outcome at three years. Rheumatology (Oxford) 2000, 39:939-949. 10.1093/rheumatology/39.9.939, 10986297.
17. Tunn EJ, Bacon PA. Differentiating persistent from self-limiting symmetrical synovitis in an early arthritis clinic. Br J Rheumatol 1993, 32:97-103. 10.1093/rheumatology/32.2.97, 8428243.
18. Chibnik LB, Mandl LA, Costenbader KH, Schur PH, Karlson EW. Comparison of threshold cutpoints and continuous measures of anti-cyclic citrullinated peptide antibodies in predicting future rheumatoid arthritis. J Rheumatol 2009, 36:706-711. 10.3899/jrheum.080895, 19228654.
19. Rönnelid J, Wick MC, Lampa J, Lindblad S, Nordmark B, Klareskog L, van Vollenhoven RF. Longitudinal analysis of citrullinated protein/peptide antibodies (anti-CP) during 5 year follow up in early rheumatoid arthritis: anti-CP status predicts worse disease activity and greater radiological progression. Ann Rheum Dis 2005, 64:1744-1749. 10.1136/ard.2004.033571, 1755292, 15843452.
20. Syversen SW, Goll GL, Heijde DM, Landewe R, Lie BA, Ødegård S, Uhlig T, Gaarder PI, Kvien TK. Prediction of radiographic progression in rheumatoid arthritis and the role of antibodies against mutated citrullinated vimentin: results from a 10-year prospective study. Ann Rheum Dis 2010, 69:345-351. 10.1136/ard.2009.113092, 19648126.
21. Ursum J, Bos WH, van Dillen N, Dijkmans BA, van Schaardenburg D. Levels of anti-citrullinated protein antibodies and IgM rheumatoid factor are not associated with outcome in early arthritis patients: a cohort study. Arthritis Res Ther 2010, 12:R8. 10.1186/ar2907, 2875634, 20064278.
22. Mjaavatten MD, Haugen AJ, Helgetveit K, Nygaard H, Sidenvall G, Uhlig T, Kvien TK. Pattern of joint involvement and other disease characteristics in 634 patients with arthritis of less than 16 weeks' duration. J Rheumatol 2009, 36:1401-1406. 10.3899/jrheum.081217, 19487273.
23. Mjaavatten MD, Uhlig T, Haugen AJ, Nygaard H, Sidenvall G, Helgetveit K, Kvien TK. Positive anti-citrullinated protein antibody status and small joint arthritis are consistent predictors of chronic disease in patients with very early arthritis: results from the NOR-VEAC cohort. Arthritis Res Ther 2009, 11:R146. 10.1186/ar2820, 2787285, 19796386.
24. Moll JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum 1973, 3:55-78. 10.1016/0049-0172(73)90035-8, 4581554.
25. Aletaha D, Huizinga TW. The use of data from early arthritis clinics for clinical research. Best Pract Res Clin Rheumatol 2009, 23:117-123. 10.1016/j.berh.2008.11.008, 19233051.
26. Harrison BJ, Symmons DP, Barrett EM, Silman AJ. The performance of the 1987 ARA classification criteria for rheumatoid arthritis in a population based cohort of patients with early inflammatory polyarthritis. American Rheumatism Association. J Rheumatol 1998, 25:2324-2330.
27. Kaarela K, Kauppi MJ, Lehtinen KE. The value of the ACR 1987 criteria in very early rheumatoid arthritis. Scand J Rheumatol 1995, 24:279-281. 10.3109/03009749509095163, 8533041.
28. Saraux A, Berthelot JM, Chales G, Le Henaff C, Thorel JB, Hoang S, Valls I, Devauchelle V, Martin A, Baron D, Pennec Y, Botton E, Mary JY, Le GP, Youinou P. Ability of the American College of Rheumatology 1987 criteria to predict rheumatoid arthritis in patients with early arthritis and classification of these patients two years later. Arthritis Rheum 2001, 44:2485-2491. 10.1002/1529-0131(200111)44:11<2485::AID-ART428>3.0.CO;2-S, 11710704.
29. Symmons DP. Classification criteria for rheumatoid arthritis--time to abandon rheumatoid factor?. Rheumatology (Oxford) 2007, 46:725-726. 10.1093/rheumatology/kel418, 17215261.
30. Mewar D, Coote A, Moore DJ, Marinou I, Keyworth J, Dickson MC, Montgomery DS, Binks MH, Wilson AG. Independent associations of anti-cyclic citrullinated peptide antibodies and rheumatoid factor with radiographic severity of rheumatoid arthritis. Arthritis Res Ther 2006, 8:R128. 10.1186/ar2017, 1779371, 16859535.
31. Klareskog L, Stolt P, Lundberg K, Kallberg H, Bengtsson C, Grunewald J, Rönnelid J, Harris HE, Ulfgren AK, Rantapää-Dahlqvist S, Eklund A, Padyukov L, Alfredsson L. A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum 2006, 54:38-46. 10.1002/art.21575, 16385494.
32. Kudo-Tanaka E, Ohshima S, Ishii M, Mima T, Matsushita M, Azuma N, Harada Y, Katada Y, Ikeue H, Umeshita-Sasai M, Miyatake K, Saeki Y. Autoantibodies to cyclic citrullinated peptide 2 (CCP2) are superior to other potential diagnostic biomarkers for predicting rheumatoid arthritis in early undifferentiated arthritis. Clin Rheumatol 2007, 26:1627-1633. 10.1007/s10067-007-0558-5, 17286215.
33. Bos WH, Wolbink GJ, Boers M, Tijhuis GJ, de Vries N, Horst-Bruinsma I, Tak PP, Stadt R, Laken CJ, Dijkmans BA, van SD. Arthritis development in arthralgia patients is strongly associated with anti-citrullinated protein antibody status: a prospective cohort study. Ann Rheum Dis 2009, 69:490-494. Published Online First: 9 April 2009., 10.1136/ard.2008.105759, 19363023.